Whether you’re trying to prevent blood clots or have been prescribed a blood thinner to treat atrial fibrillation (AFib), Eliquis (apixaban) and warfarin are two of the most commonly-used medications.
Subanalysis from Phase 3 ARISTOTLE Study Published Today in The Lancet PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today ...
PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) today announced the main results of the Phase 3 clinical trial ARISTOTLE, which ...
Pfizer and Bristol-Myers Squibb’s next-gen anticoagulant Eliquis has been stealing warfarin market share for years, but that doesn't mean it's slowing down. The drug now has new data showing it's the ...
(Reuters) The blood clot preventer Eliquis, sold by Pfizer Inc and Bristol-Myers Squibb Co, proved as effective as widely used warfarin in treating a dangerous condition known as venous ...
UPPSALA, SWEDEN — A new analysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) study confirms the benefit of apixaban (Eliquis, ...
Pfizer, Inc. ( PFE) and partner Bristol-Myers Squibb presented data on their anti-clotting drug Eliquis (apixaban) at the 2013 ESC Congress in the Netherlands. The companies presented the results on ...
PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced the main results of the Phase 3 clinical trial ARISTOTLE, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results